At Asher Biotherapeutics, we are pioneering a new approach with our cis-targeted immunotherapies. Our immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response. With this innovation, we address an inherent shortcoming of conventional immunotherapies, which indiscriminately act on multiple cell types, resulting in suboptimal efficacy and side effects.
Learn more about us at asherbio.com/about-us.
